Neurocrine Biosciences’ (NBIX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a report issued on Friday,Benzinga reports.

Several other equities research analysts also recently issued reports on NBIX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Monday, September 16th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 1st. BMO Capital Markets reduced their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. Finally, Royal Bank of Canada reduced their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a research note on Friday, October 4th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average price target of $166.00.

Neurocrine Biosciences Stock Up 0.3 %

Shares of NASDAQ:NBIX opened at $135.42 on Friday. The company has a 50 day moving average of $123.99 and a two-hundred day moving average of $130.57. Neurocrine Biosciences has a 52-week low of $110.95 and a 52-week high of $157.98. The company has a market capitalization of $13.71 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34.

Insider Activity at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the stock in a transaction on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the sale, the insider now owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Plato Investment Management Ltd lifted its stake in shares of Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after acquiring an additional 10,548 shares during the period. Swiss National Bank raised its holdings in Neurocrine Biosciences by 1.4% during the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after purchasing an additional 4,100 shares in the last quarter. Tri Ri Asset Management Corp acquired a new stake in Neurocrine Biosciences in the third quarter worth approximately $3,236,000. KBC Group NV boosted its stake in Neurocrine Biosciences by 78.3% during the 3rd quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after purchasing an additional 8,332 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Neurocrine Biosciences by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock valued at $2,238,000 after purchasing an additional 7,597 shares during the period. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.